Compound Paths Sample Clauses

Compound Paths. The concept of compound paths is important in order to understand why certain attributes may be applied differently to seemingly identical situations. Compound paths are a collection of two or more line sets where inner lines are embedded into the image. A compound path may appear the same as a grouped set of lines, but is quite different in the way it will react to being filled with color, for example. Compound paths are only really a concern when you are creating print & cut images. Non-compound image Compound Path image In the previous examples, the top two images are seen straight on and appear to be identical. However, when looking at the bottom set of images the differences become apparent. With the image on the left, from a side view we are actually looking at a grey butterfly with white spots resting on top. This is an image that is not a compound path. With the image on the right, from a side view we see that we are looking at a grey butterfly with white spots embedded into the image. Of course, as we go to cut or sketch both images with the Silhouette, they will cut out in the exact same manner, but it is important to understand that there is a difference between these images as you may wish to achieve certain effects with filling images for print & cut applications. For example: This is the same image unfilled. All parts are grouped together. If this is a non-compound image and it is filled with a color feature, this will be the result: Even though grouped together, all line sets are still just individual pieces lying on top of each other, so they are all filled with the selected fill effect. If this image has a compound path and it is filled with a color feature, this will be the result: The unfilled parts of the image cannot be filled with compound path images because these embedded areas are negative space. Compound paths can still be ungrouped to move multiple image parts around, but the action of ungrouping will immediately release the compound path and make it a non-compound path image To make a series of multiple selected images a compound path, you may right- click until the multiple parts are all selected and select Make Compound Path. Similarly, you may right-click on a compound image and select Release Compound Path to perform the opposite action. These options may also be found in the Object menu.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Compound Paths. This tool will take overlapping embedded images and either Make them into a compound path or Release the compound path.
Sample 1Sample 2Sample 3See All (5)
Compound Paths. This tool will take overlapping embedded images and either Make them into a compound path or Release the compound path. You may conversely create an internal offset condition. This feature is generally better suited for the creation of internal lines for use with sketch pens. Internal Offset Image
Sample 1Sample 2
Compound Paths. ‌ The concept of compound paths is important in order to understand why certain attributes may be applied differently to seemingly identical situations. Compound paths are a collection of two or more line sets where inner lines are embedded into the image. A compound path may appear the same as a grouped set of lines, but is quite different in the way it will react to being filled with color, for example. Compound paths are only really a concern when you are creating print & cut images.
Sample 1
Compound Paths. This tool will take overlapping embedded images and either Make them into a compound path or Release the compound path. Detach Lines When images are filled or have thick lines defined, this option may be used to detach and move the outline to create two separate images; one with just the lines and one with just the filled effects left behind.
Sample 1

Related to Compound Paths

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Combination Product The term “

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

Time is Money Join Law Insider Premium to draft better contracts faster.